Generic for Mounjarotm, it is the newest injectable for treatment of Diabetes and Obesity. Tirzepatide a GLP-1 (glucagon-like peptide 1) receptor agonist, mimics the body’s natural GLP-1, a hormone that the body naturally makes in response to food intake. As the body’s natural appetite suppressant, it lowers blood sugar. Human GLP-1 onl
Generic for Mounjarotm, it is the newest injectable for treatment of Diabetes and Obesity. Tirzepatide a GLP-1 (glucagon-like peptide 1) receptor agonist, mimics the body’s natural GLP-1, a hormone that the body naturally makes in response to food intake. As the body’s natural appetite suppressant, it lowers blood sugar. Human GLP-1 only lasts a few minutes, but Tirzepatide lasts a whole week, controlling appetite. In addition, it contains GIP (Gastric inhibitory peptide), another hormone with similar properties and found to add additional weight loss benefit. As a side effect, weight loss results because of the properties to inhibit food intake, reduce gastric emptying and change the way food we think about food as a reward. Finally, long-term weight management can be achieved with once weekly Tirzepatide injections!
A large Phase 3 study published in the New England Journal of Medicine showed that a repurposed already approved anti-diabetic medication (GLP-1 agonist) combined with a healthy diet & mild exercise leads to an average weight loss of 20%. In the study, average weight loss was 15% in the 5 mg group, 19.5% in the 10 mg group, and 20.9% in
A large Phase 3 study published in the New England Journal of Medicine showed that a repurposed already approved anti-diabetic medication (GLP-1 agonist) combined with a healthy diet & mild exercise leads to an average weight loss of 20%. In the study, average weight loss was 15% in the 5 mg group, 19.5% in the 10 mg group, and 20.9% in the 15 mg group. Moreover, 56.9% of the treatment group reached their target weights, whereas only 29% in placebo (Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., … & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity).
Week 1-4……..2.5 mg weekly.
Week 5+…….. increase dose by 2.5 mg every 2-4 weeks. Up to 72-week program.
At minimum monthly in-person or telehealth visits with provider for medication and medical oversight.
Prices are all inclusive (includes weekly or monthly visits, EKG if needed) *
$375/month or $95/week for weekly doses up to 10 mg.
Doses 1
Week 1-4……..2.5 mg weekly.
Week 5+…….. increase dose by 2.5 mg every 2-4 weeks. Up to 72-week program.
At minimum monthly in-person or telehealth visits with provider for medication and medical oversight.
Prices are all inclusive (includes weekly or monthly visits, EKG if needed) *
$375/month or $95/week for weekly doses up to 10 mg.
Doses 12.5 mg and greater $50 surcharge weekly additionally.
Available as once weekly injections as either self-administered or weekly through our clinic by our trained medical staff. Your Choice!
Side effects are usually experienced mostly in the initial weeks, can be managed and, in most cases, avoided by following provider guidelines and recommendations.
Tirzepatide is not for those with personal or family history of thyroid cancer. Most common side effects are GI related: nausea, abdominal cramping, vomiting diarrhea or constipation.
Copyright © 2023 Ormond Family Medical Center - All Rights Reserved.